NextCure/Avere merger deck unveils AVR-001 Phase 1 results and a $243M pre-close financing
NXTC has more than doubled off its 52-week low of $1.55 on elevated volume (2.1× avg).
Summary
Avere, NextCure's merger partner, presented Phase 1 data for its once-weekly oral psoriasis drug AVR-001, showing efficacy comparable to the recently approved daily drug Icotyde. A $243M pre-closing private placement will fund the combined company through Phase 2b/3 trials, but leaves legacy NextCure holders with just 1.21% ownership.
Key Events · M&A and Partnerships · NXTC
-
AVR-001 Phase 1 Data Presented
Avere's once-weekly oral IL-23RA delivered a 57% PASI 75 response rate at week 8, comparing favorably to Icotyde's 47%, with a clean safety profile. These results support advancing the program into Phase 2b trials.
-
$243M Pre-Closing Financing
A private placement of 243.4M shares—representing 55.46% of the combined company—will fund operations through the Phase 2b psoriasis readout and Phase 3 initiation, extending the cash runway into 2028.
-
Legacy NextCure Ownership Diluted to 1.21%
Post-merger, NextCure stockholders will hold only 5.3M shares, or 1.21% of the 438.8M total shares outstanding, underscoring the highly dilutive reverse merger structure.
-
Merger Expected to Close Following Financing
The reverse merger with Avere, announced July 14, 2026, is contingent on the pre-closing financing and stockholder approval. The combined company will focus on advancing AVR-001.
Analysis · NXTC · Life Sciences
A corporate presentation included in this 425 filing lays out detailed Phase 1 data for AVR-001, Avere's once-weekly oral IL-23RA targeting psoriasis and IBD. The efficacy looks comparable to Icotyde—a recently approved daily oral IL-23RA—but with the convenience of weekly dosing. Also disclosed is a pre-closing private placement of $243 million (243.4M shares at an implied price near the current $6.01 stock price) that will carry the combined company through key clinical milestones. Legacy NextCure stockholders will own only 1.21% of the combined entity, confirming the highly dilutive nature of the reverse merger announced two days ago. The new clinical data and financing details materially advance the investment thesis for the combined company.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTC was trading at $6.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.3M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.